Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. Our findings are illustrated by cases from Europe, the US, and Asia.
Rezensionen / Stimmen
From the reviews:
"This book examines the international pharmaceutical industry with special emphasis on the current and emerging research methodologies . . What distinguishes this book from others on the same subject is its emphasis on empirical findings (53 figures, 20 tables) and an exceptionally good, if short, discussion of various research technologies . . The six-page glossary of industry terms, when used with its decent index, is a particular joy. . recommend this offering to prospective managers and researchers in this industry . ." (Robert R. Rothberg, Journal of Product Innovation Management, Vol. 22, 2005)
From the reviews of the second edition:
"Leading Pharmaceutical Innovation, Gassmann and colleagues describe the current status of the pharmaceutical industry . . This book comprises seven chapters, where each could be seen as a review of the addressed topic. This helps with understanding the complexity of the challenges the pharmaceutical industry is facing, in comparison to the automotive industry or with respect to marketing problems . . book provides most valuable insight into the pharmaceutical industry from an 'outsiders' perspective." (Sandrine Shepard and Thomas Wilckens, R&D Management, Vol. 40 (5), November, 2010)
